1 / 6

Fingolimod Therapy for Multiple Sclerosis

Fingolimod Therapy for Multiple Sclerosis. Mary A. Willis, MD Neurological Institute The Mellen Center for Multiple Sclerosis Treatment and Research Cleveland Clinic Cleveland, Ohio. Anne H. Cross, MD Professor and Director John L. Trotter Multiple Sclerosis Center

shyla
Download Presentation

Fingolimod Therapy for Multiple Sclerosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fingolimod Therapy for Multiple Sclerosis Mary A. Willis, MD • Neurological Institute • The Mellen Center for Multiple Sclerosis Treatment and Research • Cleveland Clinic • Cleveland, Ohio Anne H. Cross, MD Professor and Director John L. Trotter Multiple Sclerosis Center Department of Neurology Washington University School of Medicine St. Louis, Missouri

  2. Fingolimod–Time to Benefit • MRI is surrogate measure of efficacy • In FREEDOMS and FREEDOMS II, MRI was done at baseline and 6, 12, and 24 months • Based on analysis of these data, MRI evidence of effect on inflammation and neurodegenerative pathologycan be seen early • Gadolinium-enhanced lesions were reduced versus placebo at all time points • Reduction in brain volume was observed at 6 months

  3. Key Monitoring for Fingolimod Adverse Effects • Pregnancy test for women with reproductive potential prior to starting fingolimod • Electrocardiogram prior to starting fingolimod • Refer to cardiologist if abnormal • Complete blood count and liver function tests at first follow-up after starting fingolimod(eg, at 3 months) • Ophthalmologic exam 3 to 4 months after starting fingolimod

  4. Wash-out Recommendations • No established guidelines, only recommendations based on knowledge of a drug’s kinetics or effect on blood parameter • After natalizumab • For most patients, wait 3 months before starting fingolimod • After interferon beta • No wash-outneeded • After glatiramer acetate • No wash-outneeded • After teriflunomide or dimethyl fumarate • Not yet known • For dimethyl fumarate, consider following white blood cell count to identify time to start fingolimod

  5. Do These Drugs Have Interaction Issues with Fingolimod? • Dextromethorphan hydrobromideplus quinidine sulfate used for pseudobulbar affect • Although quinidine as a class I antiarrhythmic is contraindicated, this combination product has 10-fold less quinidine • At least 1 case series has shown no adverse effects • Dalfampridine • No interaction between dalfampridine and fingolimod • Dalfampridine has low risk of induction of QT prolongation and associated cardiac arrhythmias in healthy individuals

  6. Role of Fingolimod in MS Treatment Algorithm • Approved as first-line therapy for relapsing forms of MS • Also appropriate as alternative therapy in patients with: • Breakthrough disease • Intolerable side effects • Poor adherence

More Related